{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:05:44Z","timestamp":1780427144971,"version":"3.54.1"},"reference-count":21,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T00:00:00Z","timestamp":1654992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Memorial Physician Group Infectious Disease Department"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are currently the two leading causes of death among infectious diseases. As we progress towards a \u201cnew normal\u201d, more information is required regarding post-COVID-19 syndromes. We present a case of latent tuberculosis reactivation 3 months after a successful inpatient treatment of COVID-19. A 74-year-old female from the Philippines presented with a new left mid-lung infiltrate with worsening shortness of breath and lethargy for one week prior to admission. The clinical course of the patient deteriorated despite broad-spectrum antibiotics, diuretics, and high-dose steroid therapy requiring intubation and mechanical ventilation. Her sputum culture yielded the microbiological diagnosis of TB. Anti-tubercular medications were started and the patient had a favorable clinical outcome. Our case demonstrates that immunosuppression secondary to COVID-19 and its treatments may promote the development of an active TB infection from a latent infection. It is important to be aware of this potential increase in risk during and after a COVID-19 treatment. This is especially important in high-risk populations to ensure an early diagnosis and prompt management as well as to reduce transmission.<\/jats:p>","DOI":"10.3390\/idr14030048","type":"journal-article","created":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T09:26:48Z","timestamp":1655026008000},"page":"446-452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1968-5807","authenticated-orcid":false,"given":"Ana-Alicia","family":"Leonso","sequence":"first","affiliation":[{"name":"Department of Graduate Medical Education, Memorial Hospital West, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7515-0105","authenticated-orcid":false,"given":"Kyle","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Hospital West, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Prol","sequence":"additional","affiliation":[{"name":"Department of Graduate Medical Education, Memorial Hospital West, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Rawat","sequence":"additional","affiliation":[{"name":"Department of Graduate Medical Education, Memorial Hospital West, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Khunger","sequence":"additional","affiliation":[{"name":"Department of Graduate Medical Education, Memorial Hospital West, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Bromberg","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Memorial Hospital West, Pembroke Pines, FL 33028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"n436","DOI":"10.1136\/bmj.n436","article-title":"Severe covid-19 pneumonia: Pathogenesis and clinical management","volume":"372","author":"Attaway","year":"2021","journal-title":"BMJ."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"REMAP-CAP Investigators, Gordon, A.C., Mouncey, P.R., Al-Beidh, F., Rowan, K.M., Nichol, A.D., Arabi, Y.M., Mafham, M., Bell, J.L., and Linsell, L. (2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N. Engl. J. Med., 384, 1491\u20131502.","DOI":"10.1056\/NEJMoa2100433"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., and Ustianowski, V. (2021). Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J.A., Murthy, S., Diaz, J.V., Slutsky, A.S., Villar, J., Angus, D.C., Annane, D., Azevedo, L.C.P., and Berwanger, O. (2020). Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA, 324, 1330\u20131341.","DOI":"10.1001\/jama.2020.17023"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e0492","DOI":"10.1097\/CCE.0000000000000492","article-title":"Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review","volume":"3","author":"Behal","year":"2021","journal-title":"Crit. Care Explor."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"583897","DOI":"10.3389\/fmed.2020.583897","article-title":"IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated with Increased Secondary Infections","volume":"7","author":"Kimmig","year":"2020","journal-title":"Front. Med."},{"key":"ref_8","unstructured":"World Health Organization (2020). Global Tuberculosis Report 2020, World Health Organization. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.15585\/mmwr.mm6811a2","article-title":"Tuberculosis\u2014United States","volume":"68","author":"Talwar","year":"2018","journal-title":"MMWR Morb Mortal Wkly. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Miramontes, R., Hill, A.N., Yelk Woodruff, R.S., Lambert, L.A., Navin, T.R., Castro, K.G., and LoBue, P.A. (2015). Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011\u20132012. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140881"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"814943","DOI":"10.1155\/2011\/814943","article-title":"Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection","volume":"2011","author":"Ahmad","year":"2011","journal-title":"Clin. Dev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e123-5","DOI":"10.1086\/421396","article-title":"Severe acute respiratory syndrome and pulmonary tuberculosis","volume":"38","author":"Low","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000477908","article-title":"Middle East Respiratory Syndrome Coronavirus and Pulmonary Tuberculosis Coinfection: Implications for Infection Control","volume":"60","author":"Alfaraj","year":"2017","journal-title":"Intervirology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/irv.12670","article-title":"Influenza and tuberculosis co-infection: A systematic review","volume":"14","author":"Walaza","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia","volume":"9","author":"Lin","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_17","first-page":"101344","article-title":"COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: A case report","volume":"32","author":"Khayat","year":"2021","journal-title":"Respir. Med. Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e247562","DOI":"10.1136\/bcr-2021-247562","article-title":"Reactivation of latent tuberculosis in a COVID-19 patient on corticosteroid treatment","volume":"15","author":"Friedman","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_19","unstructured":"Bhimraj, A., Morgan, R.L., Shumaker, A.H., Lavergne, V., Baden, L., Cheng, V.C.-C., Edwards, K.M., Gandhi, R., Gallagher, J., and Muller, W.J. (2021, August 15). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America 2021; Version 4.4.1. Available online: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2741\/1249","article-title":"Pharmacologic immunosuppression","volume":"9","author":"Barshes","year":"2004","journal-title":"Front Biosci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"(2000). Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the ATS and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am. J. Respir. Crit. Care Med., 161, S221-47.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/14\/3\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:28:19Z","timestamp":1760138899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/14\/3\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,12]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["idr14030048"],"URL":"https:\/\/doi.org\/10.3390\/idr14030048","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,12]]}}}